̽»¨¾«Ñ¡

Michael Yi Bonner

Michael Yi Bonner

µþ±ð²õö°ì²õ²¹»å°ù±ð²õ²õ: Solnavägen 9, 3A, 17177 Stockholm
Postadress: C2 Medicinsk biokemi och biofysik, 171 77 Stockholm

Om mig

  • My long-term goal is to become an academic investigator and establish my own
    research group, which will focus on advancing our understanding of cancer
    biology. In the short term, I am focused on cultivating the necessary skills,
    knowledge, and networks that will help me succeed. The laboratory of Prof.
    Jack L. Arbiser, MD, PhD, a pupil of the late Judah Folkman, MD, has a long
    history developing small molecules as antiangiogenic and antitumor therapies.
    The lab has both discovered natural products and synthesized novel small
    molecules. I have spent the past ten years learning the scientific techniques
    used in his research. Prior to joining the Arbiser group, I obtained a BA
    degree in Chemistry at Emory University, and I have since assisted in the
    discovery of the antiangiogenic and/ in vivo/ antitumor properties of
    honokiol, a natural product from the Magnolia tree. I have also synthesized
    honokiol analogs. In addition, I have helped synthesize and test Imipramine
    Blue, a novel NADPH oxidase inhibitor with systemic availability and
    antitumor efficacy. I have helped pioneer a novel synthesis of Solenopsin A
    (ant venom) and Solenopsin A analogs, which has been demonstrated to act as
    ceramide analogs with tumor suppressive activity. Finally, I have helped
    reveal the antitumor properties of palladium complexes, including Tris DBA
    Palladium, for clinical development.
    My previous experience with the Arbiser group has given me broad knowledge in
    biochemistry, cancer biology, and organic chemical synthesis focused towards
    pre-clinical therapeutic research. Most importantly, it has given me the
    poise and skills to pursue a professional education and career as an
    independent academic scientist. Currently I have co-authored a number of
    peer-reviewed publications, a testament to my dedication to scientific
    scholarship.
    I have since joined Prof. Rikard Holmdahl’s group at the Karolinska
    Institute in Stockholm, Sweden as a PhD candidate. I have found a Thesis
    project entitled "*Redox Modulation- Impact on Tumor Growth & Therapeutic
    Anticancer Efficacy"* that expands on my experience in angiogenesis and
    cancer biology, as well as offer new opportunities to further develop in
    Redox biology, immunology, and proteomics.
    *2022 Robert Lundberg Memorial Foundation*
    The purpose of the foundation is to promote scientific research in the field
    of tumour diseases, especially cancer.
    *2018 SWIMM Travel Award*
    Swedish Society of Immunology SWIMM
    SWIMM is a part of the Scandinavian Society for Immunology (SSI), which also
    comprises of the Danish, Finnish, Norwegian and Icelandic National Societies.
    The main goal for the society is to assemble immunologists in Sweden and work
    for the progress of basic and applied immunology. SSI award travel grants to
    applicants who fulfill our eligibility criteria.
    [1]
    *2017 Ruth L. Kirschstein Predoctoral Individual National Research Service
    Award (4 years + 1 year)*
    NIH: National Cancer Institute
    The purpose of the Kirschstein-NRSA program is to enable promising
    predoctoral students with potential to develop into a productive, independent
    research scientists, to obtain mentored research training while conducting
    dissertation research.

    [1]

Forskningsbeskrivning

  • My current project focuses on changes in the REDOX environment of leukocytes
    that stem from the Nox2 complex in murine cancer models. Specifically, I am
    focused on understanding how murine cancer models develop slower in mice
    carrying mutations in the Ncf1 (p47-phox) gene, a key component of the Nox2
    complex controlling for production of superoxide /hydrogen peroxide in
    leukocytes which is also mutated in approximately 23% of patients diagnosed
    with chronic granulomatous disease (CGD).

Artiklar

  • Article: ANTIOXIDANTS. 2021;11(1):12
    Aoun M; Cai X; Xu B; Lahore GF; Bonner MY; He Y; Backdahl L; Holmdahl R
  • Article: JOURNAL OF SURGICAL RESEARCH. 2021;264:544-552
    Cai X; Tian Y; Wu Y; Bonner MY; Zhuo X; Yuan Z
  • Article: NATURE COMMUNICATIONS. 2021;12(1):610
    Norin U; Rintisch C; Meng L; Forster F; Ekman D; Tuncel J; Klocke K; Backlund J; Yang M; Bonner MY; Lahore GF; James J; Shchetynsky K; Bergquist M; Gjertsson I; Hubner N; Backdahl L; Holmdahl R
  • Journal article: JOURNAL OF IMMUNOLOGY. 2020;204(1_Supplement):242.46
    Bonner MY; Olofsson P; Holmdahl R
  • Article: CANCERS. 2020;12(2):E395-395
    da Costa A; Bonner MY; Rao S; Gilbert L; Sasaki M; Elsey J; MacKelfresh J; Arbiser JL
  • Article: ONCOTARGET. 2019;10(43):4424-4436
    Musi E; Schwartz GK; Yoo JH; Odelberg SJ; Li DY; Bonner MY; Selvakumar P; Rao S; Gilbert LC; Elsey J; Arbiser JL
  • Article: ONCOGENE. 2017;36(41):5709-5721
    Sengupta S; Nagalingam A; Muniraj N; Bonner MY; Mistriotis P; Afthinos A; Kuppusamy P; Lanoue D; Cho S; Korangath P; Shriver M; Begum A; Merino VF; Huang C-Y; Arbiser JL; Matsui W; Gyorffy B; Konstantopoulos K; Sukumar S; Marignani PA; Saxena NK; Sharma D
  • Article: SCIENTIFIC REPORTS. 2017;7(1):11198
    Arbiser JL; Nowak R; Michaels K; Skabytska Y; Biedermann T; Lewis MJ; Bonner MY; Rao S; Gilbert LC; Yusuf N; Karlsson I; Fritz Y; Ward NL
  • Article: CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2017;42(6):645-647
    da Costa A; Bonner M; Arbiser JL
  • Article: INTERNATIONAL JOURNAL OF DERMATOLOGY. 2017;56(7):754-761
    Costa A; Facchini G; Pinheiro ALTA; da Silva MS; Bonner MY; Arbiser J; Eberlin S
  • Article: ONCOTARGET. 2016;7(43):69321-69336
    Akamata K; Wei J; Bhattacharyya M; Cheresh P; Bonner MY; Arbiser JL; Raparia K; Gupta MP; Kamp DW; Varga J
  • Article: ONCOTARGET. 2016;7(32):51651-51664
    Laidlaw KME; Berhan S; Liu S; Silvestri G; Holyoake TL; Frank DA; Aggarwal B; Bonner MY; Perrotti D; Jorgensen HG; Arbiser JL
  • Article: ONCOTARGET. 2016;7(32):51569-51580
    Diaz B; Ostapoff KT; Toombs JE; Lo J; Bonner MY; Curatolo A; Adsay V; Brekken RA; Arbiser JL
  • Article: MOLECULES. 2016;21(8):E995-995
    Medra A; Witkowska M; Majchrzak A; Cebula-Obrzut B; Bonner MY; Robak T; Arbiser JL; Smolewski P
  • Article: EXPERIMENTAL DERMATOLOGY. 2016;25(6):479-480
    Bhandarkar SS; Lanka P; Lanka LR; Veledar E; Bonner MY; MacKelfresh J; Arbiser JL
  • Article: ONCOTARGET. 2016;7(11):12857-12868
    Bonner MY; Karlsson I; Rodolfo M; Arnold RS; Vergani E; Arbiser JL
  • Article: ONCOTARGET. 2015;6(30):29947-29962
    Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
  • Article: ONCOTARGET. 2015;6(18):16396-16410
    Avtanski DB; Nagalingam A; Kuppusamy P; Bonner MY; Arbiser JL; Saxena NK; Sharma D
  • Article: NATURE COMMUNICATIONS. 2015;6:6656
    Pillai VB; Samant S; Sundaresan NR; Raghuraman H; Kim G; Bonner MY; Arbiser JL; Walker DI; Jones DP; Gius D; Gupta MP
  • Article: RADIATION RESEARCH. 2015;183(3):262-270
    Weyemi U; Redon CE; Aziz T; Choudhuri R; Maeda D; Parekh PR; Bonner MY; Arbiser JL; Bonner WM
  • Visa fler

Alla övriga publikationer

  • Corrigendum: CANCERS. 2021;13(9):2015
    da Costa A; Bonner MY; Rao S; Gilbert L; Sasaki M; Elsey J; MacKelfresh J; Arbiser JL
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2020;140(7):S114
    Costa A; Teichmann M; Bonner M; Mackelfresh J; Gilbert L; Rao S; Arbiser J
  • Conference publication: JOURNAL OF IMMUNOLOGY. 2020;204(1)
    Bonner MY; Olofsson P; Holmdahl R
  • Published conference paper: BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS. 2018;1862(11):2518-2527
    Arbiser JL; Bonner MY; Ward N; Elsey J; Rao S
  • Letter: JAMA DERMATOLOGY. 2017;153(9):931-932
    Costa A; Mackelfresh J; Gilbert L; Bonner MY; Arbiser JL
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2017;137(5):S18
    Bonner M; Pankove R; Rao S; Costa A; Shetata B; Elsey J; Arbiser JL
  • Corrigendum: BREAST CANCER RESEARCH. 2017;19(1):39
    Nagalingam A; Arbiser JL; Bonner MY; Saxena NK; Sharma D
  • Review: NPJ PRECISION ONCOLOGY. 2017;1:23
    Arbiser JL; Bonner MY; Gilbert LC
  • Review: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2016;17(4):369-385
    Costa A; Bonner MY; Arbiser JL
  • Meeting abstract: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(5):S19
    da Costa A; Govindarajan B; Bonner MY; Rao S; Arbiser J
  • Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(3):564-566
    Arbiser JL; Bonner MY
  • Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(3):561-564
    Strid J; McLean WHI; Irvine AD
  • Conference publication: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016;74(5):AB27
    Costa A; Clerici SP; Facchini G; Pinheiro A; Bonner MY; Arbiser J; Eberlin S
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2015;135:S85
    Arbiser JL; Michaels KA; Nowak RS; Bonner M; Karlsson I; Fritz Y; Ward NL
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2015;135:S31
    Bhandarkar S; Lanka P; Lanka LR; Bonner M; Mackelfresh J; Arbiser JL
  • Meeting abstract: CANCER RESEARCH. 2014;74(19):lb-61-lb-61
    Sengupta S; Bonner MY; Arbiser JL; Saxena NK; Sharma D
  • Meeting abstract: CANCER RESEARCH. 2014;74(19):lb-187-lb-187
    Avtanski DB; Bonner MY; Tiutan TP; Arbiser JL; Saxena NK; Sharma D
  • Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134:S125
    Bonner M; Karlsson I; Rodolfo M; Arnold RS; Vergani E; Arbiser J
  • Review: FUTURE MEDICINAL CHEMISTRY. 2014;6(12):1413-1422
    Bonner MY; Arbiser JL
  • Letter: JAMA DERMATOLOGY. 2013;149(8):991-992
    Spence-Shishido A; Carr C; Bonner MY; Arbiser JL
  • Visa fler

Nyheter från KI

Kalenderhändelser från KI